On December 9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis ("OA") pr…
As part of a supply agreement for the Company's five injection OA product that was amended and restated on December 22, 2020, the Company is subject to annual minimum purchase requirements for 8 years.
As part of a supply agreement entered on February 9, 2016 for the Company's three injection OA product, the Company is subject to annual minimum purchase requirements for 10 years.
The Company had product sales to one customer totaling $ 14,822 representing 11.2 % of net sales, primarily in the U.S. reporting segment during the three months ended March 28, 2026.
Bioventus Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BVS-DEBT
Debt stack $288.4M
90%
Market cache reports total debt of $288.4M.
BVS-DEBT-8419
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
Bioventus Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Bioventus Inc..
Bioventus Inc. Ownership
Holder
Name
Confidence
Evidence
BVS-OWNER-ESSEX-WOODLANDS-MANAGEMENT-INC
Essex Woodlands Management, Inc.
90%
13F overlay lists Essex Woodlands Management, Inc. as top holder; 157 tracked holders.
Bioventus Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.